Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
|Articles|February 19, 2010
- February 2010 Infectious Disease
- Volume 76
- Issue 2
Waste Not, Want Not: Drug Disposal and the Role of the Pharmacist
Author(s)Jeff D. Prescott , PharmD, RPh, Kyleigh Estler
Advertisement
To view this article in its entirety and complete the continuing education lesson, please
Articles in this issue
over 16 years ago
Finding the Right Treatment for Managing Your Acneover 16 years ago
Women's Health Watchover 16 years ago
Infectious Diseases Watchover 16 years ago
Diabetes Watchover 16 years ago
Asthma Watchover 16 years ago
Arthritis Watchover 16 years ago
Smartphones: Smart Enough for Pharmacists?over 16 years ago
Tech Product Newsover 16 years ago
Pharmacy Technology NewsAdvertisement
Related to this article
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Two recent graduates share strategies for standing out in the competitive fellowship application process.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
This quiz was created in collaboration with PTCE™.
Pharmacy professionals can leverage LinkedIn to build a professional brand, expand meaningful connections, share expertise, and create opportunities for career growth.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
Oncology Pharmacists Reduce Adverse Drug Reactions in Hematologic Cancer Care
4
Recap: Tirzepatide Is Approved to Cut Cardiovascular Risk in Type 2 Diabetes
5